| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cereblon
Cereblon (CRBN), a component of the E3 ubiquitin ligase complex . |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[2].
As a PROTAC building block, it enables the formation of bifunctional molecules that simultaneously bind an E3 ligase and a target protein, leading to selective ubiquitination and subsequent proteasomal degradation of the target protein . |
| ln Vivo |
No in vivo activity data available for this specific compound. As a chemical intermediate for PROTAC synthesis, its in vivo activity is dependent on the final PROTAC molecule it is incorporated into.
|
| Enzyme Assay |
Not applicable. As a ligand-linker conjugate, it is not typically tested directly in enzyme/receptor binding assays. Its functionality is validated post-conjugation into a complete PROTAC, which is then assessed for target binding.
|
| Cell Assay |
Not applicable. This compound is a synthetic intermediate used for conjugation; it is not tested in cell-based assays alone. Cellular activity is evaluated after it is incorporated into a full PROTAC molecule.
|
| Animal Protocol |
Not applicable. This compound itself is not administered in animal studies. In vivo studies are performed using the final PROTAC molecule synthesized with this building block.
|
| ADME/Pharmacokinetics |
Thalidomide-O-C2-acid has a molecular weight of 346.29 g/mol and a carboxylic acid group for conjugation. Standard storage is at -20degC in powder form, and in solvent at -80degC for up to one year .
|
| Toxicity/Toxicokinetics |
No toxicity data available for this specific compound. Toxicity profiling is typically conducted on the final PROTAC molecule, as the linker-ligand conjugate alone is an intermediate not intended for direct in vivo administration.
|
| References | |
| Additional Infomation |
This compound is for research use only and not for clinical use. Its primary application is in the discovery and development of PROTACs for targeted protein degradation, particularly in oncology and neurodegenerative disease research . The mechanism involves recruiting CRBN to induce ubiquitination and degradation of disease-relevant proteins.
|
| Molecular Formula |
C16H14N2O7
|
|---|---|
| Molecular Weight |
346.291564464569
|
| Exact Mass |
346.08
|
| CAS # |
2369068-42-6
|
| PubChem CID |
139370805
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
632
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCCC(=O)O
|
| InChi Key |
JDORXWYUBMQFIZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2O7/c19-11-5-4-9(14(22)17-11)18-15(23)8-2-1-3-10(13(8)16(18)24)25-7-6-12(20)21/h1-3,9H,4-7H2,(H,20,21)(H,17,19,22)
|
| Chemical Name |
3-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxypropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~721.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8878 mL | 14.4388 mL | 28.8775 mL | |
| 5 mM | 0.5776 mL | 2.8878 mL | 5.7755 mL | |
| 10 mM | 0.2888 mL | 1.4439 mL | 2.8878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
